FirstWord
79 Reports from FirstWord
-
Medical Affairs’ Role in Breaking Down Silos in Pharma
Medical Affairs’ Role in Breaking Down Silos in Pharma Breaking down silos: strategies for medical affairs professionals Commercial, R&D, market access and patient engagement silos arising from specialisation or for specific purposes may deliver locally but might not be aligned to an organisation’s ... Read More
-
Choosing the Right Channel Mix to Maximise KOL Engagement
Choosing the Right Channel Mix to Maximise KOL Engagement Know how omnichannel communications can transform your KOL relationships Effectively engaging with KOLs is critical to pharma’s business and digital communications has become central to building these relationships. But the rapid growth in th ... Read More
-
Leveraging Personalised Content to Effectively Engage with HCPs
Leveraging Personalised Content to Effectively Engage with HCPs New strategies for driving HCP engagement success with personalised content Pandemic-driven digital HCP engagement has dramatically changed healthcare professionals (HCP) expectation of the information they receive from pharma. They wan ... Read More
-
AI Opportunities in Personalised Medicine
AI Opportunities in Personalised Medicine Know how advanced AI analytics can transform your personalised medicines strategy Multimodal Artificial Intelligence (AI)-enabled analytics are integrating insights from genomics, epigenomics, metabolomics, proteomics and transcriptomics. Allied to imaging d ... Read More
-
US Public Health Spending on Biosimilars: a data driven analysis
US Public Health Spending on Biosimilars: a data driven analysis Which companies and products are shaping the US biosimilar public health spending sector? Biosimilars are a useful way to contain pharmaceutical expenditure for both payers and patients. By the end of 2020, the FDA had approved 29 bios ... Read More
-
Meeting the Scientific Communication Needs of Multiple Stakeholders
Meeting the Scientific Communication Needs of Multiple Stakeholders How can medical affairs meet the diverse scientific information needs of multiple stakeholders? The timely delivery of trusted, current and relevant scientific data to key stakeholder groups is an increasingly critical medical affai ... Read More
-
RWE in Gene Therapy: Payer Views
RWE in Gene Therapy: Payer Views How to harness RWE to win payer support for gene therapies Gene therapy developers are looking beyond rare diseases to treat a broader range of conditions. While payers are positive for new therapies that treat unmet clinical need there is a growing anxiety: can the ... Read More
-
Biosimilars: US Payer Insights
Biosimilars: US Payer Insights Why might 2023 be a good year for the US biosimilars market? Delayed regulation, stakeholder anxieties, disappointing discounts and aggressive originator defence strategies have all played their part in the sluggish US biosimilar sector development. But is that about t ... Read More
-
Transforming Clinical Trials with Digital Endpoints: Opportunities and Challenges
Transforming Clinical Trials with Digital Endpoints: Opportunities and Challenges Digital endpoints have the potential to enhance traditional clinical data, deliver a real-world assessment of the patient’s experience, and reduce the cost/time of clinical trial programs. So, where can digital endpoin ... Read More
-
Partnering in Digital Health: Pharma and Tech Companies
Partnering in Digital Health: Pharma and Tech Companies From R&D, supply chain efficiency, manufacturing, commercialisation, and patient outreach, digital technology is transforming pharma’s business. But digital health success is reliant on partnering with tech innovators that can deliver the right ... Read More
-
The Value of RWE to Commercial Teams
The Value of RWE to Commercial Teams RWE can deliver commercial value across a product’s lifecycle from informing research and identifying medical need to the effective deployment of sales forces and commercial strategy refinement. So how can RWE be used to prove value and secure regulatory approval ... Read More
-
Applying AI to Drug Discovery and Development: Issues and Challenges
Applying AI to Drug Discovery and Development: Issues and Challenges Pharma has invested heavily in Artificial Intelligence (AI) enabled technologies in the hope they would drive R&D efficiency gains. From identifying new targets and making screening more efficient to de-risking and accelerating cli ... Read More
-
Advances in Telemedicine
Advances in Telemedicine COVID-19 rapidly accelerated the use of telemedicine technologies and their acceptance by HCPs and patients is now well established. Favourable regulation and rising reimbursement is further seeing telehealth embedded in the healthcare ecosystem. So, where does pharma fit in ... Read More
-
KAM Metrics: Measuring Success
KAM Metrics: Measuring Success Are your key performance indicators (KPIs) really proving the value of your key account management (KAM) team? Too often established quantitative sales metrics are not being complemented by KPIs that prove the quality and depth of stakeholder relationships. As the use ... Read More
-
Sales Rep Metrics: Measuring Success
Sales Rep Metrics: Measuring Success As commercialising innovative products becomes ever more challenging, sales reps have had to adapt and manage HCP engagement more effectively and productively. Quantitative metrics will continue to be at the heart of sales performance measurement, but what strate ... Read More
-
Real World Evidence: The Role of Medical Affairs
Real World Evidence: The Role of Medical Affairs Real-world evidence (RWE) studies can build compelling proof of a product’s value that is increasingly influential on regulators, payers, physicians and patients. So how can medical affairs teams respond to growing demand? How can RWE be used to shape ... Read More
-
Advances in Wearable Health Technology
Advances in Wearable Health Technology With the roll out of 5G, increasingly sophisticated biosensor technologies and the establishment of digital biomarkers, wearables are expanding into clinical settings. How–and where–can pharma benefit? In what ways can wearables be used to improve patient adher ... Read More
-
Payer Perspectives on Real World Data and Evidence
Payer Perspectives on Real World Data and Evidence Compelling real-world evidence (RWE) of a product’s utility and value is increasingly critical if pharma is to win the support of payers. But how are payers using RWE, what do they want and how can pharma deliver the RWE that really informs payer de ... Read More
-
Payer Perspectives on Indication-based Pricing
Payer Perspectives on Indication-based Pricing Pharma argues that indication-based pricing would maximise the utility of products and allow wider patient access to essential medicines. Payers are not convinced. Beyond practical objections around the administrative burden such pricing models bring is ... Read More
-
Commercial Workforce Excellence: Future training strategies and priorities
Commercial Workforce Excellence: Future training strategies and priorities In the future, commercial teams will only achieve their sales objectives through intelligence-led engagement that meet the needs of customers. Personalised omnichannel engagement will dominate physician/HCP interaction. Under ... Read More
-
Orphan Drugs: New thinking on RWE generation and value
Orphan Drugs: New thinking on RWE generation and value From clinical trial planning and better education of HCPs to meeting the demands of diverse stakeholder groups, real-world evidence (RWE) is increasingly playing a pivotal role in the successful development and launch of an orphan drug. But how ... Read More
-
Recruiting for the Medical Affairs Team of the Future
Recruiting for the Medical Affairs Team of the Future As Medical Affairs transitions to a core strategic function new capabilities will be needed to meet wider commitments such as controlling the scientific narrative, generating better evidence and delivering enhanced stakeholder engagement. New ski ... Read More
-
The Role of Medical Affairs in Integrated Evidence Planning
The Role of Medical Affairs in Integrated Evidence Planning Efficient integrated evidence planning would better prepare pharma to navigate market access challenges. What’s not to like? But traditional siloed working structures are deeply embedded in many companies. Can pharma really create truly cro ... Read More
-
Cell and Gene Therapies: Accelerating uptake
Cell and Gene Therapies: Accelerating uptake Cell and gene therapies (CAGTs) are delivering on the promise of personalised medicines, meeting high unmet need and delivering powerful and curative treatments. So why is uptake so slow? The obstacles are diverse with the low volume of patients impacting ... Read More
-
Orphan Drugs: Pharma/DTC genetic testing partnerships
Orphan Drugs: Pharma/DTC genetic testing partnerships The rapidly developing field of direct-to-consumer (DTC) genetic testing offers orphan drug developers the opportunity to directly support patients and HCPs while unlocking new insights in rare diseases that can inform clinical development progra ... Read More
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook